Hammersmith Medicines Research Ltd

What Hammersmith Medicines Research Ltd does

Hammersmith Medicines Research Ltd is a London-based contract research organization (CRO) that provides clinical research services to pharmaceutical and biotechnology sponsors. Founded in 1993 by Malcolm Boyce, who continues to serve as Managing and Clinical Director, the firm has operated for over three decades in the UK clinical research market. The company is privately held and employs between 251 and 500 staff based on disclosed headcount data.

The company delivers clinical pharmacology and trial-related services typical of an established CRO, operating under UK Medicines and Healthcare products Regulatory Agency (MHRA) oversight and Good Clinical Practice (GCP) standards. Beyond its core clinical operations, the firm has limited publicly disclosed technology, product, or partnership detail; its public website (hmrlondon.com) returns only a loading/verification page in the source data, and no customer logos, product portfolio, or pricing structure are available in the supplied dataset. Leadership comprises founder Malcolm Boyce (Managing and Clinical Director) and John Swift (Chief Medical Officer).

Business model mechanics are not directly disclosed. The single documented funding event — a $55,998 grant from EISMEA in May 2015 — is non-dilutive and modest, consistent with a privately funded, operationally self-sustaining CRO rather than a venture-backed biotech. With three decades of continuous operation and a stable founder-led management team, the firm appears to generate revenue primarily through fee-for-service clinical study contracts, though specific pricing models, customer segments, and revenue figures are not available in the input data.

Name

Hammersmith Medicines Research Ltd

Website

https://hmrlondon.com

Company type

Private

Founded year

1993

Headcount range

251–500 employees

Short description

Hammersmith Medicines Research Ltd is a London-based contract research organization founded in 1993 that provides clinical research services to pharmaceutical and biotechnology sponsors, employing 251–500 staff under founder-led management.

Ownership category

akta.pro rank

Product category

Contract Research Organization Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)

Keywords

• Clinical research services
• Contract research organization
• Clinical trial services
• Pharmaceutical research
• Biotechnology research

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D

Core offering

Hammersmith Medicines Research Ltd (HMR) is a London-based contract research organization (CRO) that provides clinical research services to pharmaceutical and biotechnology companies. The company conducts clinical trials and related research activities on behalf of drug developers, supporting the development of new medicines.

Differentiator

Problem solved

Functional benefit

Products and services

• Contract Research Organization (CRO) Services Clinical research and clinical trial services provided to pharmaceutical and biotechnology sponsors on an outsourced basis, encompassing trial design, execution, and clinical study management.

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Direct peers

• Richmond Pharmacology: London-based early-phase clinical CRO operating a dedicated Phase I unit in the UK. Comparable in geography, unit size, and Phase I/IIa clinical pharmacology positioning.
• Simbec Orion: European clinical CRO with a strong focus on early-phase and Phase I/IIa studies, including operations in the UK. Comparable in size, therapeutic breadth, and biotech/sponsor customer profile to HMR.
• Celerion: Specialist early-phase clinical pharmacology CRO with extensive bed capacity across the US, UK, and EU. Closely comparable in service mix, Phase I focus, and serving biotech and large pharma first-in-human programs.
• Quotient Sciences: UK-headquartered translational and early-phase CRO offering first-in-human studies, clinical pharmacology, and drug product formulation. Directly comparable to HMR in Phase I clinical pharmacology focus and UK/European sponsor base.

Broad incumbents

• Parexel International: Full-service global CRO with significant early-phase and clinical pharmacology capabilities across the UK and EU. Represents one of the consolidating large-CRO choices for sponsors evaluating mid-sized Phase I providers.
• ICON plc: Global full-service CRO formed through the PRA Health Sciences combination. Competes with HMR for early-phase work and is a likely preferred-provider alternative for sponsors considering mid-tier UK Phase I units.
• Thermo Fisher Scientific (PPD Clinical Research): Global CRO through the PPD acquisition, with clinical pharmacology and early-development services. Represents the type of full-service incumbent that mid-sized Phase I specialists must differentiate against.
• IQVIA: Largest global full-service CRO with deep Phase I/clinical pharmacology capacity. Competes for the same sponsor budgets as HMR but offers a vastly broader service portfolio across all trial phases.
• Labcorp Drug Development (formerly Covance): Large clinical CRO with extensive early-phase clinical pharmacology operations in the UK and globally. Overlaps with HMR on Phase I services while also offering central lab and bioanalytical scale HMR cannot match.

Emerging players

• Pharmaron: China-rooted CRO/CDMO with expanding UK and US clinical pharmacology capacity. Comparable as an early-phase and integrated drug development peer, though its center of gravity is broader discovery/manufacturing.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hammersmith Medicines Research Ltd